Crinetics Pharmaceuticals EBIT

Crinetics Pharmaceuticals (CRNX) currently reports a EBIT of $-540M as of March 2026. That compares with $-380M in the prior-year period — down 42.0% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Crinetics Pharmaceuticals's EBIT history and peer comparisons.

Crinetics Pharmaceuticals's EBIT decreased from $-380M to $-540M — a 42.0% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Crinetics Pharmaceuticals's EBIT of $-540M is lower than the Healthcare sector average of $23B. That is roughly 102.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Crinetics Pharmaceuticals reported $-540M in EBIT as of March 2026. That compares with $-380M in the prior-year period — down 42.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-540M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Crinetics Pharmaceuticals, and consider following CRNX for alerts when major investors trade the stock.